BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 66 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $930,981 | -32.0% | 324,291 | +19.6% | 0.00% | – |
| Q2 2023 | $1,369,595 | +168.0% | 271,207 | +0.3% | 0.00% | – |
| Q1 2023 | $511,108 | +107050.5% | 270,428 | +1.9% | 0.00% | – |
| Q4 2022 | $477 | -99.9% | 265,290 | +0.3% | 0.00% | – |
| Q3 2022 | $447,000 | -26.2% | 264,547 | +7.2% | 0.00% | – |
| Q2 2022 | $606,000 | -49.3% | 246,708 | -42.9% | 0.00% | – |
| Q1 2022 | $1,196,000 | -43.3% | 432,024 | +9.1% | 0.00% | – |
| Q4 2021 | $2,111,000 | -28.7% | 396,167 | +13.2% | 0.00% | – |
| Q3 2021 | $2,960,000 | -32.5% | 349,980 | -2.7% | 0.00% | -100.0% |
| Q2 2021 | $4,383,000 | -39.3% | 359,602 | +20.9% | 0.00% | 0.0% |
| Q1 2021 | $7,215,000 | -16.6% | 297,437 | +10.2% | 0.00% | 0.0% |
| Q4 2020 | $8,651,000 | +15.5% | 269,925 | +9.0% | 0.00% | 0.0% |
| Q3 2020 | $7,488,000 | -2.3% | 247,726 | +36.3% | 0.00% | -50.0% |
| Q2 2020 | $7,663,000 | +239.8% | 181,764 | +101.1% | 0.00% | +100.0% |
| Q1 2020 | $2,255,000 | – | 90,397 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 3,449,845 | $104,289,000 | 4.42% |
| Boxer Capital, LLC | 2,014,858 | $60,909,000 | 2.10% |
| RA Capital Management | 2,589,904 | $78,293,000 | 1.43% |
| Artal Group S.A. | 1,521,517 | $45,995,000 | 1.12% |
| Ikarian Capital, LLC | 358,941 | $10,851,000 | 0.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 802,511 | $24,260,000 | 0.59% |
| Bellevue Group AG | 1,403,000 | $42,413,000 | 0.59% |
| Logos Global Management LP | 123,465 | $3,732,000 | 0.48% |
| Casdin Capital, LLC | 289,395 | $8,748,000 | 0.39% |
| HighVista Strategies LLC | 16,391 | $496,000 | 0.36% |